TABLE 3.
Ongoing clinical trials of PD‐1/PD‐L1 inhibitors in NSCLC patients with EGFR mutation
| NCT number | Phase | Status | Drug | Treatment | Population | Primary endpoint |
|---|---|---|---|---|---|---|
| NCT02364609 | I | Active, not recruiting | Pembrolizumab | Pembrolizumab + Afatinib | EGFR mutation with Erlotinib treatment failure | ORR, PFS |
| NCT04013542 | I | Recruiting | Nivolumab | Ipilimumab + Nivolumab + Radiation Therapy | EGFR mutation are eligible | AEs, PFS, OS, ORR, DOR |
| NCT04517526 | II | Not yet recruiting | Durvalumab |
Platinum‐based Chemotherapy + Bevacizumab + Durvalumab + Salvage SBRT |
EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR, DOR |
| NCT04426825 | II | Recruiting | Atezolizumab | Atezolizumab + Bevacizumab | EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR, DOR, AEs |
| NCT04405674 | II | Not yet recruiting | Tislelizumab | Tislelizumab + Chemotherapy | EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR, DOR, DCR |
| NCT04245085 (ABC‐lung) | II | Recruiting | Atezolizumab | Atezolizumab + Bevacizumab + Chemotherapy | EGFR mutation with EGFR‐TKI treatment failure | PFS, AEs, OS, ORR |
| NCT04120454 | II | Recruiting | Pembrolizumab | Ramucirumab + Pembrolizumab | EGFR mutation with EGFR‐TKI treatment failure | ORR, AEs, DCR, PFS, OS |
| NCT04147351 | II | Recruiting | Atezolizumab | Atezolizumab + Bevacizumab + Carboplatin/Cisplatin+Pemetrexed | EGFR mutation with EGFR‐TKI treatment failure | ORR, PFS |
| NCT04099836 | II | Recruiting | Atezolizumab | Atezolizumab + Bevacizumab | EGFR mutation with Osimertinib treatment failure | ORR, PFS, OS, AEs |
| NCT04042558 (GFPC 06‐2018) | II | Recruiting | Atezolizumab | Atezolizumab ± Bevacizumab + Platinum + Pemetrexed | EGFR mutations, ALK rearrangement or ROS1 fusion with targeted therapies failure | ORR, PFS, OS, DOR |
| NCT03994393 (ILLUMINATE) | II | Recruiting | Durvalumab + Tremelimumab | Durvalumab + Tremelimumab | EGFR mutation with EGFR‐TKI treatment failure | ORR, DCR, PFS, OS |
| NCT03513666 (JS001) | II | Active, not recruiting | Toripalimab | Toripalimab + Pemetrexed + Carboplatin | EGFR mutation with EGFR‐TKI treatment failure | ORR, PFS, OS, DOR |
| NCT02947386 | I/II | Recruiting | Nivolumab | Nivolumab + Nimotuzumab | EGFR mutation are eligible | ORR, irAEs |
| NCT03786692 | II | Recruiting | Atezolizumab | Carboplatin + Pemetrexed + Bevacizumab ± Atezolizumab | EGFR mutation in exon 19 or exon 21 | PFS, ORR, DOR |
| NCT03802240 | III | Recruiting | Sintilimab | Sintilimab ± IBI305 + Chemotherapy | EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR |
| NCT03515837 (KEYNOTE‐789) | III | Active, not recruiting | Pembrolizumab | Pemetrexed + Platinum ± Pembrolizumab | EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR, DOR |
| NCT03991403 | III | Recruiting | Atezolizumab | Atezolizumab + Combination Carboplatin + Paclitaxel + Bevacizumab | EGFR or ALK mutation | PFS, OS, ORR, DOR |
| NCT02864251 (CheckMate722) | III | Active, not recruiting | Nivolumab | Nivolumab + Chemotherapy vs. Nivolumab + Ipilimumab vs. Chemotherapy | EGFR mutation with EGFR‐TKI treatment failure | PFS, OS, ORR, DOR |
| NCT02454933 (CAURAL) | III | Active, not recruiting | Durvalumab | Durvalumab + Osimertinib vs. Osimertinib | EGFR mutation and T790M mutation with EGFR‐TKI treatment failure | AEs |
Abbreviations: NSCLC, non‐small cell lung cancer; EGFR, epidermal growth factor receptor; ORR, overall response rate; DOR, duration of response; OS, overall survival; PFS, progression‐free survival; DCR, disease control rate; PD‐L1, programmed death‐ligand 1; TKI, tyrosine kinase inhibitor; AE, adverse event; PD‐1, programmed cell death protein 1; irAE, immune‐related adverse event.